IP Library Granted Patent US 8,071,376
Granted Patent B2
US 8,071,376 · App. 11/580,625 · Granted Dec 6, 2011

Production of oligodendrocytes from placenta-derived stem cells

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,071,376
App. No.
11/580,625
Granted
Dec 6, 2011
Kind
B2
Abstract

The present invention provides methods and compositions for the production of glial cells and oligodendrocytes from placenta stem cells. The invention further provides for the use of these glia and oligodendrocytes in the treatment of, and intervention in, for example, trauma, ischemia and degenerative disorders of the central nervous system (CNS), particularly in the treatment of demyelinating diseases such as multiple sclerosis.

Claims (12)

1. A method of producing an oligodendrocyte, comprising culturing a placental stem cell under conditions and for a time sufficient for said stem cell to exhibit a characteristic of an oligodendrocyte, wherein said placental stem cell is not a trophoblast, wherein said culturing comprises contacting said stem cell with a phosphodiesterase inhibitor; and wherein said characteristic is the production of myelin oligodendrocyte specific protein (MOSP) or expression of a gene encoding MOSP.

2. The method of claim 1 , wherein said culturing comprises contacting said stem cell with isobutylmethylxanthine (IBMX).

3. The method of claim 1 , wherein said placental stem cell expresses one or more of the markers CD73, CD105, CD200, HLA-G, or OCT-4; and does not express one or more of CD34, CD38, or CD45.

4. The method of claim 1 , wherein said placental stem cell is:

CD200 + and HLA-G + ;

CD73 + , CD105 + , and CD200 + ;

CD200 + and OCT-4 + ; or

CD73 + , CD105 + and HLA-G + .

5. The method of claim 3 , wherein said placental stem cell is CD10 + , CD34 − , CD105 + and CD200 + .

6. The method of claim 1 , wherein said culturing comprises additionally contacting said placental stem cell with one or more of epidermal growth factor (EGF), fibroblast growth factor (FGF), or platelet-derived growth factor (PDGF).

7. The method of claim 1 , wherein said culturing comprises additionally contacting said placental stem cell with epidermal growth factor (EGF), fibroblast growth factor (FGF), and platelet-derived growth factor (PDGF).

8. The method of claim 1 , wherein said placental stem cells are CD10 + , CD29 + , CD54 + , CD90 + , SH2 + , SH3 + , CD34 − and CD45 − .

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 30, 2025
From: CELULARITY INC.
To: CELENIV PTE. LTD.
Reel/Frame 073705/0109 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 9, 2017
From: CLARITY ACQUISITION II LLC
To: CELULARITY, INC.
Reel/Frame 044780/0261 →
MERGER Recorded Nov 8, 2017
From: ANTHROGENESIS CORPORATION
To: CLARITY ACQUISITION II LLC
Reel/Frame 044413/0680 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 12, 2007
From: HEIDARAN, MOHAMMAD
To: ANTHROGENESIS CORPORATION
Reel/Frame 018881/0221 →